The alternative pathway dysregulation in aHUS may occur due to genetic alterations in complement factor H (most common), Factor I, Factor B, and C3, or autoantibodies against factor H. Like aHUS, complement-mediated TMA has also been described in patients with lupus nephritis and as a complication of hematopoietic stem cell transplant. The gene discussed is CFH; the disease is lupus nephritis.